LivaNova Reports First Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Livanova (LIVN) PT Lowered to $87 at Needham & Company
May 1, 2019 12:10 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Livanova (NASDAQ: LIVN) to $87.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "LIVN's 1Q19 revenue was consistent with its preannouncement and its EPS was below consensus. As expected, management lowered its 2019 revenue... More
LivaNova plc (LIVN) Misses Q1 EPS by 3c, Revenues Miss; FY19 EPS Guidance Below Consensus
May 1, 2019 6:17 AM EDTLivaNova plc (NASDAQ: LIVN) reported Q1 EPS of $0.54, $0.03 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $250.8 million versus the consensus estimate of $255.87 million.
"We are disappointed by our first quarter performance in U.S. Neuromodulation and Perceval® sales. As a leadership team, we are implementing a series of actions to counteract the market dynamic and salesforce retention issues we experienced," said Damien McDonald, Chief Executive Officer of LivaNova. "Sales results for first quarter 2019 were strong in Cardiovascular across all... More
